COVID-19 induces a hyperactive phenotype in circulating platelets

Shane P. Comer[1,2,*], Sarah Cullivan[3,*], Paulina B. Szklanna[1,2,*], Luisa Weiss[1,2,*], Steven Cullen[4], Sarah Kelliher[5], Albert Smolenski[6], Niamh Moran[4], Claire Murphy[1,7], Haidar Altaie[8], John Curran[9], Katherine O'Reilly[3,6], Brian Marsh[6,10], Sean Gaine[3,6], Brian McCullagh[3,6], Fionnuala Ní Áinle[1,5,6,11,†], Barry Kevane[1,5,6,†] and Patricia B. Maguire[1,2,12,†]. On behalf of the COCOON Study investigators [‡]

Affiliations

[1]Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin Ireland;

[2]School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland;

[3]Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland;

[4]School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland;

[5]Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland;

[6]School of Medicine, University College Dublin, Dublin, Ireland;

[7] Deparment of Paediatrics, Royal College of Surgeons in Ireland, Dublin, Ireland;

[8]SAS UK Headquarters, Wittington House, Henley Road, Medmenham, Marlow, Buckinghamshire, SL7 2EB, United Kingdom;

[9]SAS Institute Ltd, La Touche House, Dublin 1, Ireland;

[10]Department of Critical Care Medicine, Mater Misericordiae University Hospital, Dublin, Ireland;

[11]Department of Haematology, Rotunda Hospital, Dublin, Ireland;

[12]UCD Institute for Discovery, University College Dublin, Dublin, Ireland.

[*]*These authors contributed equally to this manuscript*

[†] *Corresponding authors*

[‡] See Appendix

Running title: Platelet Activity in COVID-19

Corresponding authors:

Prof Patricia B. Maguire
Conway SPHERE Research Group,
UCD Conway Institute,
University College Dublin,
Belfield, Dublin 4, Ireland
e-mail: patricia.maguire@ucd.ie

Dr Barry Kevane
Conway SPHERE Research Group,
Department of Haematology,
Mater Misericordiae University Hospital,
Eccles Street, Dublin 7, Ireland.
e-mail: barrykevane@mater.ie

Prof Fionnuala Ní Áinle
Conway SPHERE Research Group,
Department of Haematology,
Mater Misericordiae University Hospital,
Eccles Street, Dublin 7, Ireland.
e-mail: fniainle@mater.ie

Key Findings

- Routine platelet-related clinical blood parameters (MPV, PNR) are associated with disease severity in COVID-19.
- Agonist-induced ADP release is dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients.
- Circulating levels of PF4, sP-selectin levels and TPO are significantly elevated in COVID-19.
- Identification of a hyperactive platelet phenotype may warrant re-evaluation of current thrombotic prevention strategies in COVID-19 treatment.

Word Count: 2926/5000

Keywords
SARs-CoV-2, COVID-19, thrombosis, mean platelet volume (MPV), dense granule secretion, circulating platelet activation markers.

Abstract

Background

Coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, has to date affected over 13.3 million globally. Although high rates of venous thromboembolism and evidence of COVID-19-induced endothelial dysfunction have been reported, the precise aetiology of the increased thrombotic risk associated with COVID-19 infection remains to be fully elucidated.

Objectives

Here, we assessed clinical platelet parameters and circulating platelet activity in patients with severe and non-severe COVID-19.

Methods

An assessment of clinical blood parameters in patients with severe COVID-19 disease (requiring intensive care), patients with non-severe disease (not requiring intensive care), general medical in-patients without COVID-19 and healthy donors was undertaken. Platelet function and activity were also assessed by secretion and specific marker analysis.

Results

We show that routine clinical blood parameters including increased MPV and decreased platelet:neutrophil ratio are associated with disease severity in COVID-19 upon hospitalisation and intensive care unit admission. Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19.

Conclusion

Distinct differences exist in routine full blood count and other clinical laboratory parameters between patients with severe and non-severe COVID-19. Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets. These data suggest that abnormal platelet reactivity may contribute to hypercoagulability in COVID-19. Further investigation of platelet function in COVID-19 may provide additional insights into the aetiology of thrombotic risk in this disease and may contribute to the optimisation of thrombosis prevention and treatment strategies.

Introduction:

Over 13.3 million people globally have been infected since the outbreak of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; or COVID-19) in December 2019, with over 578,000 fatalities reported to date (1). COVID-19 is characterised by a marked pro-inflammatory response with fever, elevated inflammatory markers and clinical & radiological features of pneumonitis being evident among affected individuals (2). A complex interplay is known to exist between pro-inflammatory pathway activity and blood coagulation activation; this interplay appears to represent a source of morbidity among SARS-CoV-2 infected patients, particularly among those with severe disease (3). Unexpectedly high levels of venous thromboembolism (VTE) (4-10) have been reported in this patient group and levels of D-dimer (a marker of increased blood coagulation activation) have been shown to correlate with disease severity and appear to be predictive of mortality (11, 12). COVID-19 patients with cardiovascular risk factors (hypertension, diabetes) have been indentified as being particularly at risk of thrombotic events (13-16). Moreover, recent post-mortem studies have shown evidence of widespread thrombosis in pulmonary vasculature and other organs (17, 18).

Anti-platelet drugs (such as aspirin) and anti-coagulants (such as low molecular weight heparin (LMWH)) are known to be effective in the prevention and treatment of arterial and venous thrombosis (19-21). High rates of VTE despite LMWH thromboprophylaxis have been reported in COVID-19 and emerging reports of unusual or severe arterial thrombotic events have been published (5, 18, 22-24). As both arterial and venous thrombosis can have devastating consequences, efforts to determine the precise molecular mechanisms underlying the unique hypercoagulable state in COVID-19 must be prioritised in order to optimise preventative and therapeutic strategies (25, 26).

Circulating platelets, the activity of which are central to haemostasis and thrombosis, are now understood to fulfill a much broader role in the regulation of a myriad of biological processes including inflammation, wound healing and angiogenesis (27). Platelet-mediated immune responses induced by viral infection have previously been reported (28-31) and a recent report has demonstrated altered platelet gene expression profiles and functional responses in patients infected with COVID-19 (32). Moreover, thrombocytopenia has been noted in

response to dengue (33, 34) and SARS-CoV infection (35) and among in-patients with COVID-19, thrombocytopenia appears to be associated with increased risk of in-hospital mortality (3, 36). Increased mean platelet volume (MPV), a sensitive indicator of circulating platelet activity and a prognostic marker in thromboinflammation (37-39), has also been reported in association with specific viral infections (40).

In the present study, we aimed to characterise patterns of platelet activity among patients infected with COVID-19 relative to that observed in non-affected hospitalised patients in order to determine if platelet dysfunction or hyperactivity contributes to COVID-19-induced hypercoagulability.

Methods:

Patient recruitment and blood collection

Ethical approval to proceed with this study (1/378/2077) was granted by the Institutional Review Board of the Mater Misericordiae University Hospital. Anonymised datasets describing clinical laboratory parameters among hospitalised patients with severe COVID-19 (requiring critical care support), non-severe COVID-19 (not requiring critical care) and non-COVID-19 affected medical inpatients were compiled from routine clinical testing results. SARS-CoV-2 infection was confirmed in all cases by RT-PCR analysis of nasopharyngeal swab specimens. Informed consent was sought prior to obtaining additional blood samples for analysis from a sub-group of patients with severe COVID-19, non-severe COVID-19 and hospitalised patients without COVID-19, with patients matched for age, body mass index (BMI) & gender. All patients were recruited at the Mater Misericordiae University Hospital, Dublin, Ireland. A group of healthly control donors were also recruited. Exclusion criteria consisted of age <18 years and exposure to aspirin or other anti-platelet agents in the preceding 2 weeks.

30 ml of blood was collected via venepuncture with a 21-gauge needle into a 10 mL acid citrate dextrose (ACD) vacutainer and centrifuged (200 xg with no brake for 15 min at room temperature (RT). Platelet rich plasma (PRP) was isolated and the pH adjusted to 6.5 with ACD and supplemented with 1 μM PGE_1. Platelets were then isolated from plasma by centrifugation (600 $\times$ g for 10 min at RT) and platelet-poor-plasma was stored at -80°C.

Platelet ATP secretion assay

Isolated platelets from severe COVID-19 (n=6), non-severe COVID-19 (n=4) and hospitalised control (n=3) patient groups and healthy controls (n=6) were washed using a modified Tyrode's buffer (130 mM NaCl, 9 mM $NaHCO_3$, 10 mM Tris-HCl, 10 mM Trisodium citrate, 3 mM KCl, 0.81 mM KH_2PO_4, 9 mM $MgCl_2$ x $6H_2O$; pH 7.4 with ACD) followed by centrifugation (600 xg for 10 min at RT). Platelets were again resuspended in modified Tyrode's buffer and incubated at 37°C until the ATP secretion assay was performed. Platelet counts were obtained so that the secretion assay results could be normalised to 10^6 platelets/ml.

ATP secretion was measured using a luminescence-based assay, as previously described (41-44). Agonists and buffer (5µl), were dispensed in duplicate into 96-well plates, together with 35µl of washed platelets and incubated for 3 minutes at 37 °C, with fast orbital shaking. The doses of platelet agonists used to induce platelet ATP secretion were as follows; thrombin: 0.1 U/ml, 0.5 U/ml; U46619: 1 µM, 6.6 µM. Following incubation, 5µl of ATP detecting reagent (chronolume; Labmedics, UK) was dispensed into each well and luminescence was measured immediately using a Perkin Elmer 1420 96-well plate reader. Data was expressed as the amount of ATP secreted, in luminescence arbitrary units (AU), and converted to pmoles ATP released per 10^6 platelets by comparison with the luminescence recorded from an ATP standard (0.4 mM).

Enzyme-linked immunosorbent assay (ELISA)

ELISAs for thrombopoietin (DTP00b), P-selectin (DPSE00), and platelet factor 4 (DPF40) were purchased from R&D Systems (Abingdon, UK) and performed according to the manufactures instructions. In brief, undiluted or 1:40 diluted platelet poor plasma (PPP) was added in triplicate to wells for thrombopoietin and PF4, respectively. After incubation, the plates were washed and incubated with the respective conjugate. For P-selectin, 1:20 diluted PPP was added simultaneously with the P-selectin conjugate and incubated. Again, plates were washed and the substrate added. The reaction was stopped with stop solution and the optical density was determined at 450 nm within 30 minutes on a Dynex DS2 (Dynex Technologies, Worthing, UK). Protein quantification was performed using a 4 parametric logistic or log-logit regression.

Statistical analysis

Statistical analysis was performed using R (version 4.0.0) and SAS Viya© software (version 3.5). Data were tested for normal distribution using a Shapiro-Wilk test. Normally distributed continuous FBC data were presented as mean ± standard deviation and assessed for statistical significance using a one-way ANOVA. Differences in ATP release and protein expression were determined using a two-tailed *t*-test. In both cases, *p*-values were adjusted for multiple comparisons using a Holm-Bonferroni post-hoc test. Categorical data were described as percentages and significance was tested using a Fisher's exact test. Values below 0.05 were regarded as statistically significant. Data visualisation was performed using SAS Viya©.

Results:

Mean platelet volume (MPV) and platelet-to-neutrophil ratio (PNR) are associated with disease severity in COVID-19

Clinical laboratory data were available for 54 patients with confirmed SARS-CoV-2 infection. Within this group, 34 patients had developed severe disease requiring transfer to the intensive care unit (ICU) for ventilatory support while the remaining 20 patients did not require critical care support at any stage during the course of their hospital admission. Laboratory parameters relating to these two distinct subgroups of patients with COVID-19 (severe COVID-19, n=34; non-severe COVID-19, n=20) were compared to data from an age and gender-matched cohort of hospitalised medical inpatients without COVID-19 (n=20). Day of admission was defined as the day patients were admitted to the Mater Misericordiae University Hospital.

In agreement with previous studies (45, 46), higher levels of D-dimer were observed on the day of hospital admission among the patients who subsequently developed severe COVID-19 (mean±SD; 4.95±6.36 mg/L) in comparison ($p=0.0.012$) to that observed in the non-severe COVID-19 group (1.01±0.75 mg/L) (Table 1). Furthermore, a significantly higher mean platelet volume (MPV, $p=0.015$) and neutrophil count ($p=0.013$) in addition to a significantly lower platelet-neutrophil ratio (PNR, $p=0.0067$) was noted on the day of admission in the group of patients who subsequently developed a severe disease course relative to that seen in the non-severe group (Fig. 1A). Interestingly these significant differences remained following transfer to intensive care (Fig. 1B).

While platelet counts did not differ on the day of admission between patients subsequently designated to have had either a severe or non-severe disease course (Fig. 1A), significantly decreased platelet counts were observed among the severe COVID-19 patients at the time of transfer to the ICU relative to the non-severe group ($p=0.014$, Fig. 1B). These findings are in agreement with previous studies, which have suggested that a lower platelet count is associated with severe COVID-19 (3, 47-49). An increased neutrophil-to-lymphocyte ratio (NLR) in severe cases relative to non-severe was also detected at the time of hospital admission (another previously reported predictor of disease severity) (Supplementary Fig. 1) (47, 50, 51).

Agonist-induced ADP release is dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients.

Recently published data have suggested a crucial mechanistic role for platelets in the pathophysiology of COVID-19 (18, 32, 52). We assessed dense granule release following platelet activation with various platelet agonists. ATP secretion was used as a surrogate marker for dense granule secretion, given that the ratio of ADP to ATP in platelet dense granules is a constant 2:3 ratio (53).

Platelets from individuals within each group were isolated and activated with low and high concentrations of thrombin and U46619. Platelets from COVID-19 patients exhibited significantly higher levels of dense granule secretion when compared to both control cohorts (HeC and HoC) with no significant difference between severe and non-severe COVID-19 patients (Fig. 2). Low doses of thrombin (0.1 U/ml) and U46619 (1 μM) induced minimal activation in platelets isolated from healthy and hospitalised control patients. In contrast, dramatically increased dense granule secretion was observed upon platelet activation in patients with COVID-19 (Fig. 2A, 2C and Supplementary Table 2). Platelet stimulation with 0.1U/mL thrombin increased ADP-release 3-fold in COVID-19 patients compared with HeC and HoC (Fig. 2A and Supplementary Table 2). Crucially, platelet activation with the thromboxane A_2 receptor agonist U46619 (1μM) induced a 28-fold increase in ADP-release in COVID-19 positive patients compared to HeC and strikingly, an 89-fold increase between COVID-19 positive patients and HoC (Fig. 2C and Supplementary Table 2). Platelet stimulation with high-dose thrombin (0.5 U/ml) and U46619 (6.6 μM) induced a 2-fold and 10-fold increase respectively, in dense granule secretion from COVID-19 patients compared to controls (Fig. 2B, 2D and Supplementary Table 2). These data suggest that platelets from COVID-19 patients are more responsive to low dose agonist stimulation when compared to control platelets, potentially indicating a reduced activation threshold in COVID-19 patients.

Circulating levels of PF4, sP-selectin and TPO are significantly elevated in COVID-19.

To further characterise this hyperactive platelet phenotype, circulating plasma markers of platelet activity were measured in each of the above study groups (n=6 per group; platelet-poor plasma was available from an additional 2 non-severe COVID patients and an additional

3 hospitalised controls). Circulating levels of platelet factor 4 (PF4) were substantially elevated in COVID-19 patients when compared to both hospitalised (HoC) and healthy controls (HeC) ($p=0.012$ and $p=0.0033$, respectively; Fig. 3A). Nonetheless circulating PF4 levels could not differentiate between severe and non-severe COVID-19 patient cohorts ($p=0.85$). On the other hand, circulating levels of soluble P-selectin (sCD62P) also increased in COVID-19 patients when compared to our control cohorts (Fig. 3B) and intriguingly, could differentiate between our non-severe and severe COVID-19 cohorts ($p=0.037$), suggesting that elevated sP-selectin may be associated with disease severity.

Increased thrombopoetin (TPO) levels have been reported in SARs-CoV infection and more recently in COVID-19 (only in comparison to healthy controls) (54). Within our study population, TPO levels were found to be significantly higher among patients with COVID-19 (combined severe and non-severe) compared to HeC ($p=0.0021$; Fig. 3C). No significant difference in circulating TPO levels was noted between COVID-19 and HoC patients ($p=0.71$; Fig. 3C). Interestingly, TPO levels between our severe and non-severe COVID-19 cohorts showed a clear trend towards elevated circulating TPO in severe COVID-19 infection ($p=0.052$; Fig. 3C).

Discussion

We have demonstrated that distinct platelet-related patterns in full blood count and other clinical laboratory parameters appear to be associated with the development of a more severe disease course in our cohort of COVID-19 patients, reflecting other recently published data (2, 47, 55). Therewithal, we also report novel findings which indicate that COVID-19 is associated with abnormal platelet reactivity. Our observations are likely to be of significant clinical and translational relevance in view of the uncertainty that currently exists with regards to the aetiology of thrombotic risk in COVID-19 and the optimal strategy for prevention and treatment of thrombosis in this population.

In addition to the previously reported observations that neutrophilia, lymphopenia, elevated D-dimer, elevated neutrophil-to-lymphocyte ratio and elevated platelet-to-lymphocyte ratio appear to be associated with severe disease, we have reported that within our cohort a significantly lower platelet-to-neutrophil ratio was observed on the day of admission among the COVID-19 patients who subsequently progressed to require critical care support (5, 11, 12, 47, 56). While platelet counts did not specifically differ between groups on day of hospitalisation, we did observe increased levels of thrombopoietin in all COVID-19 positive patients, potentially indicating the presence of a stimulus for increased thrombopoeisis in this group. Moreover, a greater MPV was observed on the day of hospital admission in the group of COVID-19 patients who subsequently developed a severe disease course requiring transfer to intensive care. Enlarged platelets express more platelet activation markers (57) and contain more granules (58) and the release of such granular contents (e.g. thromboxane, ADP and β-thromboglobulin) (59) can drive further platelet activation.

Other investigators have demonstrated increased platelet aggregation in response to low-dose agonist stimulation in COVID-19 patients as well as increased platelet thromboxane generation (32, 60). In line with these findings, we observed increased platelet responsiveness (ADP release) to low-dose agonist stimulation, within our population of COVID-19 patients. Intriguingly, previous reports have demonstrated similar patterns of enhanced platelet reactivity in response to subthreshold concentrations of agonists in the presence of dengue virus nonstructural protein 1 (34, 61), potentially indicating a virus-induced sensitisation of platelets. As ADP/ATP and thromboxane A2 are locally-acting autocrine agonists which rapidly amplify platelet activation triggering more release of platelet granule contents, our findings provide further evidence that platelets from COVID-19 patients are more reactive, a phenomenon which may contribute to thrombotic risk (4-10).

The circulating levels of the platelet activation markers PF4 and sP-selectin were highly elevated among our cohort of COVID-19 positive patients compared to controls which futher supports the hypothesis that COVID-19 is associated with enhanced platelet activation. The elevated levels of TPO in COVID-19 also aligned with previous findings (32). While circulating levels of PF4 did not differentiate between severe and non-severe COVID-19 cases, sP-selectin was higher among the severe COVID-19 group, in keeping with previous reports (60, 62). Other investigators have also reported that sP-selectin levels were elevated in COVID-19 complicated by acute respiratory distress syndrome (ARDS) (63), with even higher levels detected in patients who subsequently died (64). The mechanism underlying platelet activation in COVID-19 has been speculated to involve MAP kinase pathway (32) and/or PKCδ (60) activation, however the initial trigger remains unidentified. Crucially, Zaid *et al.* detected mRNA for angiotensin-converting enzyme 2 (ACE2), the membrane receptor that facilitates SARS-CoV-2 internalisation, in platelets (60), but it remains to be determined if platelets are directly infected by the virus. Potential alternative pathways may include internalisation of the virus or the virus genome or binding to other cell surface receptors (e.g. FcγRIIA or Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin), as observed with other viral infections (33, 65-68).

This study has a number of limitations. Firstly, our cohort of patients is relatively small, a factor which (at least in part) is likely to be related to the success of the Irish healthcare system in suppressing transmission of the virus during the early stages of the pandemic. Additionally, given the public health restrictions that were in place during the period of this study, recruitment of healthy controls was substantially impeded and consequently the available healthy controls were not appropriately matched for age relative to our COVID-19 group and hospitalised control group. Due to the small sample size, adjustment for confounding factors was not possible.

In conclusion, it has been apparent since the early stages of the COVID-19 pandemic that derangements of haemostasis represent a hallmark of this disease and appear to be associated with significant morbidity (12, 69). Several investigators have reported data suggesting that rates of venous thromboembolism are high in this population and that these thrombotic complications appear to occur despite compliance with standard VTE prevention protocols (5, 7). Reports of unusual and devastating cases of arterial thrombosis are also emerging (18, 22-24). The safety and efficacy of conventional anti-platelet and anti-coagulant treatment strategies in the management of this thrombotic risk is becoming a major focus of

translational and clinical interest. The aetiology of hypercoagulability in COVID-19 is likely multi-factorial but it is presumed to be driven by the marked inflammatory response which arises following infection (70, 71). It remains to be determined whether standard thrombosis prevention strategies require modification in order to be effective in the prevention of 'immunothrombosis' in COVID-19 or if prevention strategies should focus instead on addressing the 'upstream' inflammatory response driving coagulation activation. Our data indicate that platelets from patients infected with COVID-19 display a hyperactive phenotype, a factor which may contribute to thrombotic risk. Consequently, further characterisation of platelet dysfunction in COVID-19 and the evaluation of anti-platelet therapy as an adjunct to current thrombosis prevention measures is clearly warranted.

Acknowledgements

We thank John Crumlish, Áine Lennon, Jane Culligan, Charlotte Prior, Wendy Keogh and Julie McAndrew of the Department of Pathology, Mater Misericordiae University Hospital, for the help in preparing blood samples and ELISA experiments. We also thank Annette Wallace of Conway Stores for her invaluable help. We also thank all patients who gave consent and donated blood to this study. Finally, we thank all frontline healthcare workers in Ireland for their dedication and professionalism during the COVID-19 pandemic.

Conflicts of Interest

The authors declare that they have no actual or potential conflicts of interest with the contents of this article.

Author Contribution

S.P. Comer, P.B. Szklanna, L. Weiss, F. Ní Áinle, B. Kevane and P.B. Maguire designed the research and wrote the paper. S.P. Comer, P.B. Szklanna and L. Weiss performed experiments, and analysed data. S. Cullen performed the ATP secretion assay. S. Cullivan, S. Kelliher, F Ní Áinle and B. Kevane identified and recruited patients to the study. A. Smolenski, N. Moran, C. Murphy, K. O'Reilly, B. Marsh, S. Gaine and B. McCullagh

contributed to research design and paper writing. H. Altaie and J. Curran contributed data analytics support and expertise.

Funding

This work was supported by funding from Science Foundation Ireland (COVID-19 Rapid Response; 20/COV/0157).

Appendix

Additional investigators of the COCOON Study (all in Ireland unless stated)

Peter Doran (Scientific Director, UCD Clinical Research Centre), Jack Lambert (Dept.of Infectious Diseases, Mater Misericordiae University Hospital/UCD School of Medicine), Gerard Sheehan (Dept.of Infectious Diseases, Mater Misericordiae University Hospital/UCD School of Medicine), Tara McGinty (Dept.of Infectious Diseases, Mater Misericordiae University Hospital/UCD School of Medicine), Colman O'Loughlin (Dept.of Critical Care, Mater Misericordiae University Hospital), Jennifer Hastings (Dept.of Critical Care, Mater Misericordiae University Hospital), Mairead Hayes (Dept.of Critical Care, Mater Misericordiae University Hospital), Margaret Doherty (Dept.of Critical Care, Mater Misericordiae University Hospital), Frances Colreavy (Dept.of Critical Care, Mater Misericordiae University Hospital), Ian Conraic-Martin (Dept.of Critical Care, Mater Misericordiae University Hospital), Peter McMahon (Dept. of Radiology, Mater Misericordiae University Hospital/UCD School of Medicine) Leo Lawler (Dept. of Radiology, Mater Misericordiae University Hospital/UCD School of Medicine), Dermot O'Callaghan (Dept.of Respiratory Medicine, Mater Misericordiae University Hospital), Tomas Breslin (Dept.of Emergency Medicine, Mater Misericordiae University Hospital/UCD School of Medicine), Cian McDermott (Dept.of Emergency Medicine; Mater Misericordiae University Hospital/UCD School of Medicine), Robert Turner (Dept.of Critical Care Medicine; Mater Misericordiae University Hospital/UCD School of Medicine), John Crumlish (Laboratory Manager, Mater Misericordiae University Hospital), Aine Lennon (Dept. of Haematology, Mater Misericordiae University Hospital), Wendy Keogh (Dept. of Haematology, Mater Misericordiae University Hospital), Jane Culligan (Dept. of Haematology, Mater Misericordiae University Hospital), Siobhán McClean (UCD School of Biomolecular & Biomedical Science/UCD Conway Institute), Jennifer Donnelly (Dept. of Obstetrics, Rotunda Hospital), Mary Higgins (Dept. of Obstetrics, National Maternity Hospital), Annemarie O'Neill (Founder, Thrombosis Ireland Patient Organization), Rachel Rosovsky (Massachusetts General Hospital/Harvard Medical School, Massachusetts, USA), Karen Schreiber (Dept. of Rheumatology, Copenhagen University Hospital, Denmark), Cliona Ní Cheallaigh (Dept. of Infectious Diseases/Director of Inclusion Medicine, St James's Hospital/TCD School of Medicine), Mary Cushman (Dept. of Medicine & Pathology, Vermont Medical Center & Larner College of Medicine, University of Vermont, Vermont, USA), Saskia Middeldorp (Academic Medical Centre, Amsterdam, the

Netherlands), Peter Juni (Dept. of Medicine, St Michaels Hospital & University of Toronto, Canada), Michelle Sholzberg (Dept. of Medicine, St Michaels Hospital & University of Toronto, Canada).

References:

1.   Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.

2.   Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.

3.   Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-20.

4.   Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020.

5.   Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020.

6.   Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. Circulation. 2020.

7.   Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020.

8.   Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020.

9.   Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020.

10.   Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.

11.   Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054-62.

12.   Tang N, Li D, Wang X, Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020.

13.   Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020:cvaa106.

14.   Cheng P, Zhu H, Witteles RM, Wu JC, Quertermous T, Wu SM, et al. Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Curr Cardiol Rep. 2020;22(5):34-.

15.   Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg. 2020:S0741-5214(20)31157-5.

16.   Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373-4.

17.   Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. New England Journal of Medicine. 2020.

18.   Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine. 2020.

19.   Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Annals of internal medicine. 2007;146(4):278-88.

20.   Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6(3):405-14.

21.   Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. The New England journal of medicine. 2018;378(8):699-707.

22.   Hernandez-Fernandez F, Valencia HS, Barbella-Aponte RA, Collado-Jimenez R, Ayo-Martin O, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain. 2020.

23.   Kashi M, Jacquin A, Dakhil B, Zaimi R, Mahe E, Tella E, et al. Severe arterial thrombosis associated with Covid-19 infection. Thromb Res. 2020;192:75-7.

24.   Mestres G, Puigmacia R, Blanco C, Yugueros X, Esturrica M, Riambau V. Risk of peripheral arterial thrombosis in COVID-19. J Vasc Surg. 2020.

25.   Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40.

26.   Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology. 2020;75(23):2950.

27.   van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nature Reviews Cardiology. 2019;16(3):166-79.

28.   Guo L, Rondina MT. The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases. Frontiers in Immunology. 2019;10(2204).

29.   Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362-.

30.   Hottz ED, Bozza FA, Bozza PT. Platelets in Immune Response to Virus and Immunopathology of Viral Infections. Front Med (Lausanne). 2018;5:121-.

31.   Ali RA, Wuescher LM, Worth RG. Platelets: essential components of the immune system. Curr Trends Immunol. 2015;16:65-78.

32.   Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben CJ, et al. Platelet Gene Expression and Function in COVID-19 Patients. Blood. 2020.

33.   Ojha A, Nandi D, Batra H, Singhal R, Annarapu GK, Bhattacharyya S, et al. Platelet activation determines the severity of thrombocytopenia in dengue infection. Scientific reports. 2017;7:41697.

34.   Chao CH, Wu WC, Lai YC, Tsai PJ, Perng GC, Lin YS, et al. Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage. PLoS pathogens. 2019;15(4):e1007625.

35.   Chen R-F, Chang J-C, Yeh W-T, Lee C-H, Liu J-W, Eng H-L, et al. Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS). Microbes Infect. 2006;8(1):122-7.

36.   Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. Journal of Thrombosis and Haemostasis. 2020;n/a(n/a).

37.   Bath PMW, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagulation & Fibrinolysis. 1996;7(2):157-61.

38.   Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Current pharmaceutical design. 2011;17(1):47-58.

39.   Handtke S, Thiele T. Large and small platelets-(When) do they differ? J Thromb Haemost. 2020.

40.   Sharma K, Yadav A. Association of Mean Platelet Volume with Severity, Serology & Treatment Outcome in Dengue Fever: Prognostic Utility. J Clin Diagn Res. 2015;9(11):EC01-EC3.

41.   Mitrugno A Moran N, Metharom P. Platelets — Allies of Tumour Cells. In: The Non-Thrombotic Role of Platelets in Health and Disease: InTech; 2015. p. 109-24.

42.   Lombardi F, De Chaumont C, Shields DC, Moran N. Platelet signalling networks: pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding. Platelets. 2012;23(1):17-25.

43.   Sun B, Tandon NN, Yamamoto N, Yoshitake M, Kambayashi J. Luminometric assay of platelet activation in 96-well microplate. BioTechniques. 2001;31(5):1174, 6, 8 passim.

44.   Mitrugno A, Williams D, Kerrigan SW, Moran N. A novel and essential role for FcgammaRIIa in cancer cell-induced platelet activation. Blood. 2014;123(2):249-60.

45.   Garcia-Olivé I, Sintes H, Radua J, Abad Capa J, Rosell A. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir Med. 2020;169:106023-.

46.   Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324-9.

47.   Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.

48.   Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8.

49.   Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. Jama. 2020;323(15):1488-94.

50.   Liu Z, Li X, Zhang M, Huang X, Bai J, Pan Z, et al. The role of Mean Platelet Volume/platelet count Ratio and Neutrophil to Lymphocyte Ratio on the risk of Febrile Seizure. Scientific reports. 2018;8(1):15123.

51.   Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases. 2020;95:332-9.

52.   Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. New England Journal of Medicine. 2020;382(20):e60.

53.   Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. Journal of clinical pathology. 1988;41(12):1322-30.

54.   Yang M, Ng MHL, Li CK, Chan PKS, Liu C, Ye JY, et al. Thrombopoietin levels increased in patients with severe acute respiratory syndrome. Thrombosis research. 2008;122(4):473-7.

55.   Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation. 2020;130(5):2620-9.

56.   Qu R, Ling Y, Zhang Y-h-z, Wei L-y, Chen X, Li X-m, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. Journal of Medical Virology. 2020;n/a(n/a).

57.   Breimo ES, Østerud B. Studies of biological functions in blood cells from individuals with large platelets. Platelets. 2003;14(7-8):413-9.

58.   Colkesen Y, Muderrisoglu H. The role of mean platelet volume in predicting thrombotic events. Clinical Chemistry and Laboratory Medicine (CCLM). 2012;50(4):631.

59.   Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2010;8(1):148-56.

60.   Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19. medRxiv. 2020:2020.06.23.20137596.

61.   Quirino-Teixeira AC, Rozini SV, Barbosa-Lima G, Coelho DR, Carneiro PH, Mohana-Borges R, et al. Inflammatory signaling in dengue-infected platelets requires translation and secretion of nonstructural protein 1. Blood Adv. 2020;4(9):2018-31.

62.   Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology.

63.   Hariri L, Hardin CC. Covid-19, Angiogenesis, and ARDS Endotypes. New England Journal of Medicine. 2020.

64.   Sakamaki F, Ishizaka A, Handa M, Fujishima S, Urano T, Sayama K, et al. Soluble form of P-selectin in plasma is elevated in acute lung injury. American journal of respiratory and critical care medicine. 1995;151(6):1821-6.

65.   Koupenova M, Corkrey HA, Vitseva O, Manni G, Pang CJ, Clancy L, et al. The role of platelets in mediating a response to human influenza infection. Nature Communications. 2019;10(1):1780.

66.   Boilard E, Paré G, Rousseau M, Cloutier N, Dubuc I, Lévesque T, et al. Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation. Blood. 2014;123(18):2854-63.

67.   Hottz ED, Oliveira MF, Nunes PCG, Nogueira RMR, Valls-de-Souza R, Da Poian AT, et al. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. Journal of thrombosis and haemostasis : JTH. 2013;11(5):951-62.

68.   Wang J, Zhang W, Nardi MA, Li Z. HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia. J Thromb Haemost. 2011;9(3):562-73.

69.   Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, et al. COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection. Blood. 2020.

70.   Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020.

71.   Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.

Table 1: Clinical characteristics of hospitalised control patients without COVID-19 on admission and non-severe and severe patients with confirmed COVID-19 on admission. Results are presented as mean±SD.

	Hospitalised Controls (n=20)	Non-severe COVID19 (n=20)	Severe COVID19 (n=34)	p-value
Age (years)	64.2 ± 17.9	69.25 ± 17.7	59.4 ± 10.5	0.066
Male, n (%)	10 (50%)	13 (65%)	21 (62%)	0.682
PCT (%)	0.262 ± 0.11	0.246 ± 0.10	N/A	0.626
P-LCR (%)	25.40 ± 9.34	23.43 ± 7.57	N/A	0.47
PT (s)	13.56 ± 6.92	13.26 ± 2.02	13.87± 5.47	0.886
aPTT (s)	28.84 ± 14.17	29.22 ± 1.99	33.08± 8.35	0.272
Fibrinogen (g/L)	5.46 ± 1.72	4.65 ± 1.64	5.58 ± 1.74	0.544
D-Dimer (mg/L)	2.53 ± 1.62	1.01 ± 0.75	4.95 ± 6.36	**0.027**

PCT – plateletcrit; PLCR – platelet-large cell ratio; PT – prothrombin time; aPTT – activated partial thromboplastin time

Figure Legends

Figure 1: Routinely clinical laboratory parameters are associated with disease severity in COVID-19.

Platelet counts, MPV, Neutrophil counts and Platelet-to-neutrophil ratios of patients with severe (n=34) or non-severe (n=20) COVID-19 and hospitalised controls (n=20). **(A)** On the day of admission, patients who subsequently developed severe COVID-19 had significantly higher MPV (*p*=0.015) and neutrophil counts (*p*=0.013) and significantly lower platelet-to-neutrophil ratio (PNR, *p*=0.0067) compared to those who did not subsequently develop severe COVID-19. **(B)** On day 7 of hospitalisation, non-severe COVID-19 patients had a significantly higher platelet count compared to severe COVID-19 patients on the day of transfer to intensive care (*p*=0.014). Statistical analysis was performed using a two-tailed *t*-test and p-values were adjusted for multiple comparisons using a Holm-Bonferroni post hoc test.

Figure 2: Agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients.

Platelet dense granule release was measured in duplicate in severe (n=5) and non-severe (n=4) COVID-19 patients compared to hospitalised (n=3) and healthy controls (n=6). Platelets were stimulated with 0.1 U/ml thrombin **(A)**, 0.5 U/ml thrombin **(B)**, 1 µM U46619 **(C)**, and 6.6 µM U46619 **(D)** and ATP release (surrogate for ADP) was measured using a Chronolume luciferase assay. ADP release is expressed as pmol/10^6 platelets. Statistical analysis was performed using a two-tailed *t*-test and p-values were adjusted for multiple comparisons using a Holm-Bonferroni post hoc test.

Figure 3: Circulating levels of PF4, sP-selectin levels and TPO were significantly elevated in COVID-19. (A) Platelet factor 4 (PF), **(B)** soluble P-selectin (sCD62P), and **(C)** thrombopoietin (TPO) plasma levels from patients with severe (n=6) and non-severe (n=6) COVID-19 compared to hospitalized (n=6) and healthy (n=6) controls were measured in triplicate by ELISA. Statistical analysis was performed using a two-tailed *t*-test and p-values were adjusted for multiple comparisons using a Holm-Bonferroni post hoc test.

Comer, Cullivan, Szklanna, Weiss et al. Figure 1

0.1 U/ml thrombin

0.5 U/ml thrombin

1 μM U46619

6.6 μM U46619

Comer, Cullivan , Szklanna, Weiss et al. Figure 2

Comer, Cullivan, Szklanna, Weiss et al. Figure 3